secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001213900-23-033507
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara reports positive Phase 1a data for TARA-002 in NMIBC; plans Phase 2 trial in 2H2023
--------------------------------------------------------------------------------

- TARA-002 well tolerated at all three doses; no dose-limiting toxicities; 40KE dose selected for further trials.
- Of 3 evaluable CIS patients, 1 heavily pre-treated BCG-unresponsive patient achieved complete response; tumor regression in other 2.
- ADVANCED-2 Phase 1b/2 trial to enroll up to 102 CIS patients (BCG-naïve and BCG-unresponsive) starting 2H2023.
- Company expects current resources to fund operations into 2025, supporting clinical plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023033507/0001213900-23-033507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023033507/ea177564-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-033507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer